Role of aldosterone in diabetic nephropathy

被引:34
作者
Cha, DR
Kang, YS
Han, SY
Jee, YH
Han, KH
Kim, HK
Han, JY
Kim, YS
机构
[1] Korea Univ, Dept Internal Med, Ansan, South Korea
[2] Inha Univ, Inchon, South Korea
关键词
aldosterone; diabetic nephropathy; monocyte chemotactic peptide-1(MCP-1); spironolactone;
D O I
10.1111/j.1440-1797.2005.00455.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In the last 10 years, many studies have focused on the non-classical action of aldosterone. One of the most important new aspects of aldosterone is its pathogenic role as proinflammatory and profibrotic molecules. It has been reported that aldosterone induces myocardial fibrosis and vascular inflammation through upregulation of various proinflammatory and profibrotic cytokines. We investigated the effect of aldosterone and spironolactone, which is a non-selective mineralocorticoid receptor antagonist, on monocyte chemoattractant peptide (MCP-1) and collagen synthesis in cultured mesangial and tubular epithelial cells. In addition, to evaluate the effect of spironolactone on diabetic nephropathy, we used Otsuka Long-Evans Tokushima Fatty (OLETF) rats which are known type 2 diabetic animal models. Spironolactone treatment did not induce any significant change in blood glucose levels and blood pressure. However, spironolactone therapy significantly inhibited urinary albumin and MCP-1 excretion. Spironolactone treatment also suppressed renal mRNA expression for MCP-1, macrophage migration inhibitory factor (MIF) as well as intrarenal protein synthesis for ED-1 and MIF Morphologically, spironolactone treatment significantly prevented glomerulosclerosis, collagen deposition and connective tissue growth factor (CTGF) expression in diabetic rats. In cultured cell experiments, aldosterone directly increased the MCP-1, collagen secretion and spironolactone treatment abolished aldosterone-induced MCP-1 and collagen synthesis. Surprisingly, aldosterone treatment did not induce any significant change in TGF beta 1 gene transcription. Finally, we found that NF-kB activity was increased after stimulation with aldosterone and spironolactone therapy inhibited their activation. In addition, prior treatment with pyrrolidine dithiocarbamate (PDTC), which is a NF-KB inhibitor, inhibited aldosterone-induced MCP-1 protein secretion. These results suggest that aldosterone blockade could play a role in preventing the progression of diabetic nephropathy via anti-inflammatory and antifibrotic mechanisms.
引用
收藏
页码:S37 / S39
页数:3
相关论文
共 21 条
[1]   Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats [J].
Blasi, ER ;
Rocha, R ;
Rudolph, AE ;
Blomme, EAG ;
Polly, ML ;
McMahon, EG .
KIDNEY INTERNATIONAL, 2003, 63 (05) :1791-1800
[2]   TRENDS IN THE PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERTENSION IN THE ADULT US POPULATION - DATA FROM THE HEALTH EXAMINATION SURVEYS, 1960 TO 1991 [J].
BURT, VL ;
CUTLER, JA ;
HIGGINS, M ;
HORAN, MJ ;
LABARTHE, D ;
WHELTON, P ;
BROWN, C ;
ROCCELLA, EJ .
HYPERTENSION, 1995, 26 (01) :60-69
[3]   Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype [J].
Cicoira, M ;
Zanolla, L ;
Rossi, A ;
Golia, G ;
Franceschini, L ;
Cabrini, G ;
Bonizzato, A ;
Graziani, M ;
Anker, SD ;
Coats, AJS ;
Zardini, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (07) :1808-1812
[4]   Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity [J].
Feria, I ;
Pichardo, I ;
Juárez, P ;
Ramírez, V ;
González, MA ;
Uribe, N ;
García-Torres, R ;
López-Casillas, F ;
Gamba, G ;
Bobadilla, NA .
KIDNEY INTERNATIONAL, 2003, 63 (01) :43-52
[5]   Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats [J].
Fujisawa, G ;
Okada, K ;
Muto, S ;
Fujita, N ;
Itabashi, N ;
Kusano, E ;
Ishibashi, S .
KIDNEY INTERNATIONAL, 2004, 66 (04) :1493-1502
[6]   Expression of connective tissue growth factor in human renal fibrosis [J].
Ito, Y ;
Aten, J ;
Bende, RJ ;
Oemar, BS ;
Rabelink, TJ ;
Weening, JJ ;
Goldschmeding, R .
KIDNEY INTERNATIONAL, 1998, 53 (04) :853-861
[7]   Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats [J].
Kelly, DJ ;
Wilkinson-Berka, JL ;
Ricardo, SD ;
Cox, AJ ;
Gilbert, RE .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (06) :985-991
[8]   IMMUNOHISTOCHEMICAL AND BIOCHEMICAL-EVIDENCE FOR A CARDIOVASCULAR MINERALOCORTICOID RECEPTOR [J].
LOMBES, M ;
OBLIN, ME ;
GASC, JM ;
BAULIEU, EE ;
FARMAN, N ;
BONVALET, JP .
CIRCULATION RESEARCH, 1992, 71 (03) :503-510
[9]   Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats [J].
Miric, G ;
Dallemagne, C ;
Endre, Z ;
Margolin, S ;
Taylor, SM ;
Brown, L .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (05) :687-694
[10]   Spironolactone and angiotensin receptor blockerin nondiabetic renal diseases [J].
Nitta, K ;
Uchida, K ;
Nihei, H .
AMERICAN JOURNAL OF MEDICINE, 2004, 117 (06) :444-445